Abstract
Novartis will pay $50 million up front for access to Conatus’ pan-caspase inhibitor emricasan, a small molecule in Phase II studies to treat nonalcoholic steatohepatitis (NASH). The deal adds another drug for the fatty liver disease to Novartis’ portfolio, which already includes an FXR agonist in Phase II trials. The companies will split the costs of a Phase IIb study of emricasan; if successful, Novartis will test it in combination with an FXR agonist. As new drugs offer cures for people with hepatitis C, NASH is forecast to become the leading cause of liver transplants by 2020.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.